ARHGAP12 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma cell line. This product provides a genetically mixed pool of cells with targeted disruption of the ARHGAP12 gene, enabling loss-of-function studies without clonal selection. The polyclonal format preserves heterogeneous genetic backgrounds, facilitating robust functional comparisons to parental HT29 cells in experiments requiring consistent population-level responses.
HT29 cells are a well-characterized epithelial cell line established from a primary colorectal adenocarcinoma of a female patient. They are widely employed as a model for intestinal epithelial biology and colorectal cancer research, exhibiting features of differentiated enterocytes under specific culture conditions. Their adherent growth and epithelial morphology make them suitable for studying cell?Ccell adhesion, polarity, and migration, all processes intimately linked to ARHGAP12 function.
ARHGAP12 encodes a Rho GTPase-activating protein that accelerates GTP hydrolysis of RhoA, Rac1, and Cdc42, converting them to inactive GDP-bound states. This regulatory activity places ARHGAP12 at a critical node in the Rho GTPase cycle, where it opposes activation by guanine nucleotide exchange factors. Loss of ARHGAP12 leads to sustained GTP-loading of RhoA, Rac1, and Cdc42, which in turn promotes downstream effectors such as ROCK1/2, mDia, PAK1/2, WAVE, WASP, and N-WASP. These effectors drive actin polymerization, focal adhesion dynamics through vinculin and paxillin, and integrin-mediated signaling complexes involving FAK. Upstream, ARHGAP12 is regulated by integrin-mediated adhesion, growth factor receptors including EGFR and MET, SRC-family kinases, and cell?Ccell contact signals. Thus, its disruption in HT29 cells perturbs a coordinated network that integrates extracellular cues with cytoskeletal organization.
In the HT29 colorectal adenocarcinoma background, ARHGAP12 knockout models the consequences of lost negative regulation on Rho GTPase signaling, mirroring events that promote tumor cell motility and metastasis. Sustained RhoA activity can enhance actomyosin contractility, while persistent Rac1 and Cdc42 activation drives lamellipodial and filopodial protrusions, collectively facilitating cell migration and invasion. Concurrently, altered adhesion dynamics via cadherin and integrin pathways may reduce cell?Ccell cohesion, a hallmark of epithelial-to-mesenchymal transition. This polyclonal knockout population thus offers a relevant system to dissect how ARHGAP12 loss contributes to colorectal cancer progression without the confounding effects of clonal variation.
This knockout model is ideally suited for a range of experimental approaches, including wound healing and transwell invasion assays to quantify migration and invasive capacity, immunofluorescence microscopy to visualize actin cytoskeleton reorganization and focal adhesion morphology, and Rho GTPase activity pull-down assays to biochemically confirm sustained activation. It also serves as a platform for screening anti-metastatic compounds and studying RhoGAP family functional genomics. Phospho-signaling analysis of FAK and ERK can link ARHGAP12 loss to downstream signaling events. The polyclonal nature ensures resilience in population-based assays, making it a valuable tool for both mechanistic and translational colorectal cancer research. For further information, please contact Ascent Research.
